Гизаар may be part of symptomatic management for the long-term control of high blood pressure, applied in clinical settings that involve acute or unstable symptom patterns where a combined strategy is considered relevant for easing symptoms. It is commonly used across conditions presenting with acute episodes of Essential Hypertension and is applied in addressing the need to help reduce the risk of stroke in specific high-risk patients.

---

Targeting Uncontrolled Chronic Hypertension

This medicine is commonly used across conditions presenting with acute episodes of Essential Hypertension when high pressure readings persist despite initial monotherapy. The combination is used for managing symptom clusters that may become intense or disruptive, particularly symptoms that create noticeable physiological strain. This use supports maintaining a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load.

Quick Fact: Relief for Pressure Overload

The combination is relevant in contexts involving heightened systemic burden, supporting the patient during episodes of increased discomfort by helping to ease symptoms linked to organ-specific functional stress.

---

Reducing Cardiovascular Risk in High-Risk Patients

Гизаар is specifically applied to help reduce the risk of stroke in hypertensive patients who also have a diagnosis of Left Ventricular Hypertrophy (LVH). This application provides supportive relief and may assist with managing the severity of chronic pressure-related symptoms and supports general well-being by contributing to the preservation of long-term cardiovascular health.

Гизаар (a combination of losartan and hydrochlorothiazide) is prescribed primarily for the treatment of high blood pressure (hypertension). It is also indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.

Who Can Use Гизаар?

This medication is typically intended for adults whose blood pressure is not adequately controlled with either losartan or hydrochlorothiazide alone. It is used as an initial therapy only when the hypertension is severe enough that a combination is warranted. Dosage adjustments are not generally needed for elderly patients with normal renal function.

Who Cannot Use Гизаар?

Гизаар is contraindicated in several patient groups due to the risk of serious complications. It must not be used in:

• Pregnant women: The medication can cause injury and death to the developing fetus, particularly during the second and third trimesters. It must be discontinued immediately if pregnancy is detected.
• Patients with anuria (inability to urinate).
• Individuals with hypersensitivity (allergy) to any component of the product, or to other sulfonamide-derived drugs (due to the hydrochlorothiazide component).
• Patients with severe renal impairment (creatinine clearance le 30 mL/min) or hepatic impairment (liver problems).
• Patients with diabetes who are also taking medication containing aliskiren.

Use in children under 18 has not been established. Patients with conditions like volume depletion, electrolyte imbalance, or severe congestive heart failure require careful monitoring and may need dose adjustments.

The combination of losartan and hydrochlorothiazide (Гизаар) can interact with several other medications, which may alter the effects of one or both drugs or increase the risk of adverse reactions. It is crucial to inform your healthcare provider of all prescription, over-the-counter drugs, vitamins, and herbal products you are taking.

Key Interactions

Interacting Drug Class/Substance	Potential Effect and Clinical Concern
Potassium Supplements/Potassium-Sparing Diuretics (e.g., amiloride, spironolactone, triamterene), Salt Substitutes containing Potassium	Increased risk of hyperkalemia (high potassium levels).
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (e.g., ibuprofen, naproxen, celecoxib)	May reduce the blood pressure-lowering effect of losartan; can increase the risk of kidney function deterioration, particularly in the elderly or dehydrated.
Lithium	Increased serum lithium concentrations, leading to a risk of lithium toxicity. Lithium levels must be monitored closely.
Other Antihypertensives (e.g., ACE inhibitors, aliskiren)	Dual blockade of the Renin-Angiotensin System (RAS) is generally not recommended, as it increases the risk of hypotension, hyperkalemia, and kidney problems.
Cholestyramine/Colestipol	May reduce the absorption of the hydrochlorothiazide component, lessening its effect. Dosing must be separated by several hours.

Additional monitoring is necessary when this medication is used concurrently with antidiabetic agents (including insulin), corticosteroids, or certain cholesterol-lowering medicines. Alcohol consumption while taking this medication can also increase the risk of dizziness and low blood pressure.

Гизаар is a fixed-dose combination containing losartan and hydrochlorothiazide, operating via two distinct, complementary pharmacodynamic mechanisms.

Losartan and its active carboxylic acid metabolite function as selective, competitive antagonists of the Angiotensin II Type 1 ( AT1) receptor. By blocking AT1 receptors located in vascular smooth muscle and the adrenal gland, losartan prevents the binding of the potent endogenous vasoconstrictor, Angiotensin II. This antagonism inhibits the AT1-mediated signaling cascade, resulting in vasodilation and a reduction in aldosterone secretion. System-level physiological consequences include modulated peripheral vascular resistance and decreased plasma volume, leading to reduced systemic vascular load.

Hydrochlorothiazide acts as a thiazide diuretic in the distal renal tubules. Its molecular target is the Na^+- Cl^- cotransporter, which it inhibits, thereby decreasing the reabsorption of sodium and chloride ions. This inhibition increases the renal excretion of Na^+, Cl^-, and water, which subsequently lowers total blood volume. This dual action modulates systemic pressure via both vascular tone and volume regulation.

The medicine Гизаар, a fixed-dose combination of losartan and hydrochlorothiazide, is administered via the oral route as a film-coated tablet that should be swallowed whole with water. The standard dosing regimen for this medicine involves once-daily administration, and the tablet may be taken with or without food. The initial dose described for controlling essential hypertension is typically the 50 mg / 12.5 mg strength taken once daily. This combination is generally not intended for the initial treatment of high blood pressure; rather, it is used when blood pressure is not adequately controlled by monotherapy.

The official dosing schedule permits titration, or an increase in the dose, up to a maximum daily strength of 100 mg / 25 mg. This adjustment to the next dosage level is typically considered only after the patient has been treated with the current dosage for approximately three weeks, which establishes a long-term, step-wise pattern of use.

Official usage instructions outline specific procedural constraints for initiation. The fixed combination is not recommended as initial therapy for patients who are volume- or salt-depleted; this underlying physiological status must be corrected prior to use. Furthermore, its administration is not recommended in patients with severe hepatic impairment or severe renal impairment (CrCl < 30 mL/min), primarily due to the thiazide diuretic component. Consistent with protocols for most long-term, once-daily medications, a missed dose is usually omitted, and the subsequent dose is taken at the regularly scheduled time, rather than doubling the dose. The fixed combination is also not recommended for use in pediatric patients due to insufficient established experience.

Evidence Overview for Managing Essential Hypertension

Research has explored the use of the losartan/hydrochlorothiazide combination primarily through Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that aggregate data from multiple studies. These research settings focused on adults whose high blood pressure was not adequately controlled when they were taking losartan alone. The studies focused on monitoring outcomes related to systemic or functional imbalance, such as changes in Office Blood Pressure and 24-hour Ambulatory Blood Pressure measurements.

The research reported patterns observed in the trials detailing measured changes in blood pressure readings with the combination regimen compared to when losartan was used as a single medication. However, the evidence collected largely reflects short-term follow-up durations, often lasting only a few weeks to a few months. Therefore, limited information for long-term outcomes is available regarding the long-term patterns of blood pressure maintenance over many years.

---

Research on Monitoring the Rate of Stroke in High-Risk Patients

Research monitored the rate of a major cardiovascular event, including stroke, in a highly defined group of hypertensive patients. This research was evaluated in a long-term Randomized Controlled Trial, lasting nearly five years. The study populations included adults with hypertension and Left Ventricular Hypertrophy (LVH).

The long-term trial described patterns related to the rate of stroke events observed between the group receiving this combination and the group receiving the specific comparator regimen. However, research highlights that this particular finding was not observed in the subgroup of Black patients who were enrolled in the trial. This finding data show patterns related to only the specific high-risk population with LVH, meaning the results apply only to the populations studied.

---

Studies in Specific Patient Groups, Including Pediatric Use

Dedicated short-term, double-blind RCTs were conducted for pediatric use, with patients spanning ages 6 to 17 years. These studies monitored outcomes reflecting daily functioning or activity level by measuring changes in Sitting Trough Blood Pressure over a brief treatment period. A primary limitation of this evidence is that the follow-up durations were limited, and there is limited information for long-term outcomes regarding major clinical endpoints in this younger population.

Common questions about Гизаар (FAQ)

Q: What is Гизаар and what is it used for?

Гизаар is a combination medicine containing the active ingredients Losartan and Hydrochlorothiazide. According to official product information, its primary use is to treat high blood pressure, medically known as hypertension. It is also indicated to lower the risk of stroke in patients with hypertension who have left ventricular hypertrophy.

Q: What should I do if I miss a dose?

Regulatory documents describe the standard procedure for a missed dose: if it is remembered, it is generally recommended to take it as soon as possible, unless it is close to the time of the next scheduled dose. If the next dose time is near, the missed dose is typically skipped, and the regular schedule is resumed. The product information cautions against taking a double dose to compensate for a missed one.

Q: Can I stop taking Гизаар once my blood pressure is under control?

Treatment for high blood pressure with Гизаар is usually managed over the long term. Official product information indicates that abrupt discontinuation of this medication is not recommended, even if blood pressure appears to be controlled. If an individual wishes to stop treatment, consulting a healthcare professional is necessary.

Q: Does Гизаар affect blood sugar or cholesterol levels?

Official information and studies show that the Hydrochlorothiazide component in Гизаар may sometimes influence metabolic markers. This includes potentially causing small increases in blood glucose or lipid (cholesterol) levels in some individuals. In some cases, monitoring of these levels may be advised by a healthcare provider during therapy.

Q: Can I drink alcohol while taking Гизаар?

According to the official product information, the combination of alcohol and Гизаар may increase the risk of developing low blood pressure, or hypotension. This effect could potentially cause dizziness or fainting. Official product information suggests that individuals may need to limit or avoid alcohol due to this potential interaction.

Q: Does Гизаар cause tiredness or fatigue?

Fatigue and tiredness are listed in the regulatory documents as possible side effects associated with Гизаар. As the body adjusts to the medication, these effects are usually mild. If persistent or severe fatigue is experienced, consulting a healthcare professional is recommended according to safety guidelines.

Q: Is it safe to drive after taking Гизаар?

Some people may experience temporary side effects like dizziness or lightheadedness when starting Гизаар or when a dose adjustment occurs. If a patient experiences dizziness or lightheadedness, regulatory information recommends caution with activities like driving or operating machinery until their response to the medication is known.

Q: How long does it take for Гизаар to start lowering blood pressure?

While the active components begin working shortly after the initial dose, the overall blood pressure-lowering effect of Гизаар usually builds up over time. Studies indicate that the maximum therapeutic benefit on blood pressure may not be seen until several weeks of consistent use. Maintaining a consistent daily regimen is important for achieving and sustaining this benefit.

How to Store and Dispose of Гизаар?

Гизаар (Losartan Potassium and Hydrochlorothiazide) must be stored under specific regulatory conditions to maintain its stability and effectiveness.

Storage Requirements

The tablets require storage at Controlled Room Temperature (CRT), specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in the original container and the container must remain tightly closed. For safety, the product must always be stored out of the reach of children.

Disposal Instructions

Unused or expired Гизаар must be disposed of according to local regulations. Patients should utilize a drug take-back program if one is available in their community, as recommended by official health guidelines for the safe disposal of medicines.